159 filings
8-K
FWBI
First Wave BioPharma Inc
22 Mar 24
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
5:00pm
8-K
FWBI
First Wave BioPharma Inc
18 Mar 24
First Wave BioPharma Announces Two Abstracts on Celiac Disease Research Accepted for Presentation at the 2024 Digestive Disease Week (DDW) Conference
4:40pm
8-K
FWBI
First Wave BioPharma Inc
14 Mar 24
Latiglutenase is a potentially first-in-class oral biotherapeutic for the treatment of celiac disease
6:09am
8-K
FWBI
First Wave BioPharma Inc
5 Mar 24
First Wave BioPharma, Inc. to raise approximately $4.0 million of Gross Proceeds in Registered Direct Offering
5:26pm
8-K
FWBI
First Wave BioPharma Inc
4 Jan 24
First Wave BioPharma Chairman and CEO Issues Letter to Shareholders Highlighting Recent Accomplishments and Outlook for 2024
8:22am
8-K
ayq5wr6u 0r
27 Dec 23
First Wave BioPharma Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $4.8 Million Gross Proceeds Priced
5:23pm
8-K
iadgfx7usrxxyf287y7
27 Dec 23
First Wave BioPharma Announces Streamlining of Clinical Pipeline with Non-Binding Term Sheet to Sell Niclosamide IBD Program
6:15am
8-K
akr3 zap3
18 Dec 23
Other Events
7:00am
8-K
nni5lph
14 Dec 23
First Wave BioPharma Announces 1-for-20 Reverse Stock Split and Results of the Special Meeting of Stockholders
9:15am
8-K
jdexd4q80vdirymlb4
31 Oct 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
5:21pm
8-K/A
v64jihnn ued0z76ge
10 Oct 23
Financial Statements and Exhibits
4:06pm
8-K
9924dt
15 Sep 23
Entry into a Material Definitive Agreement
4:05pm
8-K
b2l6i28325fhxqx
14 Sep 23
First Wave BioPharma Announces Exclusive Global License Agreement for Capeserod from Sanofi
6:19am
8-K
1x1dyw tnqnxdlb
25 Aug 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:05pm
8-K
h77fq8wjpc5s
18 Aug 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:05pm
8-K
g7eeymi8a mr
21 Jul 23
First Wave BioPharma, Inc. Announces Pricing of $2.1 Million Public Offering
8:19am
8-K
3q4johs7 da
13 Jul 23
First Wave BioPharma Announces Initial Topline Results from Phase 2 SPAN Clinical Trial Investigating Enhanced Adrulipase Formulation
12:00am
8-K
vz12o69bgw
23 Jun 23
Submission of Matters to a Vote of Security Holders
4:05pm
8-K
v00be a8ocmfj7em1
16 Jun 23
Entry into a Material Definitive Agreement
4:23pm
8-K
0cfrd1
21 Apr 23
Departure of Directors or Certain Officers
4:31pm